Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014
- 1 June 2015
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S91-S93
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLBlood, 2014
- Therapy-related AML: A slip of the lip can sink a shipLeukemia Research, 2014
- The evolving challenge of therapy-related myeloid neoplasmsBest Practice & Research Clinical Haematology, 2013
- Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta‐analysisBritish Journal of Haematology, 2013
- Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cellsExperimental Hematology, 2011
- The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AMLBlood, 2011
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 TrialJournal of Clinical Oncology, 2011
- Cytogenetic and genetic pathways in therapy-related acute myeloid leukemiaChemico-Biological Interactions, 2010
- Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001